<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01465906</url>
  </required_header>
  <id_info>
    <org_study_id>TG1015TLT</org_study_id>
    <nct_id>NCT01465906</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phrase: IV

      Indication: dyspnea symptom of chronic obstructive pulmonary disease (COPD)

      Objective: to evaluate efficacy and safety of tulobuterol patch combined with Tiotropium
      bromide for relieving dyspnea symptom of COPD

      Design: a multi-centre randomized parallel blank control study

      Case number: test group 80, control group 80, totally 160

      Site number:7

      Study period: 2010.9 - 2011.8
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFT values (pulmonary function test, see description below)</measure>
    <time_frame>3 months</time_frame>
    <description>IC (inspiratory capacity) 、PEF (peak expiratory flow)、FVC (forced vital capacity)、FEV1 (forced expiratory volume in the first second)、%FEV1 (forced expiratory volume in the first second as predicted)、RV (residual volume)、TLC (total lung capacity)、RV/TLC% (residual volume/total lung capacity as percentage), etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRC （Medical Research Council） grade</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SGRQ （St. George's questionnaire） score</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>tulobuterol combined with tiotropium bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium bromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tulobuterol</intervention_name>
    <description>patch, 2mg, qN, 3 months</description>
    <arm_group_label>tulobuterol combined with tiotropium bromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide</intervention_name>
    <description>18ug, inhale, qD, 3 months</description>
    <arm_group_label>Tiotropium bromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide</intervention_name>
    <description>18ug, inhale, qD, 3 months</description>
    <arm_group_label>tulobuterol combined with tiotropium bromide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  people aging from 40 to 80 with self ability of judgment

          -  out-patients diagnosed as stable COPD according to &quot;diagnosing and treatment guideline
             of COPD (2007 edition)&quot; by Respiratory Department of Chinese Medical Association

          -  PFT value at screen phase meet the standard as follows: FEV1/FVC &lt; 70% and FEV1% among
             30%-80% 15 mins after inhalation of 400ug Ventolin (i.e., moderate and severe COPD
             patients ).

          -  people who can use Tiotropium Bromide powder inhalation device

          -  people who join the study voluntarily and sign ICF (Informed Consent Form)

        Exclusion Criteria:

          -  people who have other acute or chronic respiratory diseases which may cause impairment
             of pulmonary function such as asthma

          -  AECOPD （acute exacerbation of COPD）

          -  people who got respiratory failure 1 month before the study

          -  people who received oral corticoid treatment 1 month before the study

          -  people who undergo oxygen therapy at home because of respiratory failure

          -  people who are allergic to β2 receptor agonist such as tulobuterol

          -  patients with Skin diseases such as atopic dermatitis, who are not appropriate to use
             transdermal patch

          -  patients of hyperthyroidism, hypertension, heart disease and severe arrhythmia,
             diabetes mellitus, who are not appropriate to useβ2 receptor agonist

          -  patients who have undergone pulmonary lobectomy or have tumor

          -  active tuberculosis patients

          -  people who got acute respiratory tract infection in a month or during screening phase

          -  allergic rhinitis patients

          -  glaucoma patients

          -  people who have diseases which may cause dysuria such as prostatic hypertrophy or
             bladder neck occlusion

          -  gestation, lactation and child-bearing age women who don't agree to take contraceptive
             measures during the study

          -  people with abnormal live or kidney function, people with nervous system diseases,
             malignant tumor, neutropenia or other progressive basic diseases.

          -  People who are mental retardation, mentally ill, deaf-mute or uncooperative, who
             cannot correctly describe their disease or do corresponding respiratory questionnaire.

          -  People who are allergic to atropine and its derivatives (including tiotropium bromide
             and ipratropium bromide), lactose or any inhalant components.

          -  people who have taken part in other medical clinical trial

          -  other conditions that investigators think not appropriate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunxue Bai, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2011</study_first_posted>
  <last_update_submitted>November 8, 2011</last_update_submitted>
  <last_update_submitted_qc>November 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Chunxue Bai</investigator_full_name>
    <investigator_title>Director of Respiratory Department , Shanghai Zhongshan Hospita</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Tulobuterol</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

